Biopharmaceutical Contract Manufacturing Market Research 2022: Impact of COVID-19 and Global Analysis by Downstream, Upstream, Fill and Finish, Analytical and Quality Control, Packaging

DUBLIN, March 28, 2022–(COMMERCIAL WIRE)–The “Biopharmaceutical Contract Manufacturing Market Forecast to 2028: Impact of COVID-19 and Global Analysis by Product, Service, Source and Geography” Report has been added to offering.

The biopharmaceutical contract manufacturing market is projected to reach US$27,868.50 million by 2028 from US$15,735.04 million in 2021; it is expected to grow at a CAGR of 8.5% from 2021 to 2028.

The increase in outsourcing by pharmaceutical companies is one of the most important factors driving the growth of the market. A few years ago, the contract manufacturing industry was a niche service market that offered additional manufacturing capacity or specific services to pharmaceutical companies.

The rise of CMOs was fueled by the growing number of drug manufacturing failures. In the past, pharmaceutical companies have contracted manufacturing facilities to develop innovative drugs. However, to reduce the risk of overcapacity, the demand for manufacturing outsourcing has continuously increased.

Revolo Biotherapeutics recently partnered with contract development and manufacturing organization (CDMO) – Northway Biotech – to manufacture Revolo’s 1805 immunoregulatory binding protein. The partnership included services from cell line development to quality-assured protein manufacturing and regulatory compliance support. Similarly, Gland Pharma manufactures Remdesivir for four companies, including Mylan, from 2021.

Likewise, the organization increased its manufacturing quotas due to the high demand of the companies. In 2019, Samsung Biologics and GI Innovation signed a contract for immunochemotherapy. Under this agreement, Samsung Biologics provided services ranging from f-cell line development to Phase I drug production.

The increasing number of contracts between biopharmaceutical companies and contract manufacturing companies shows an increasing market size for the biopharmaceutical contract manufacturing market.

Based on the product, the market is segmented into biologics and biosimilars. The biological products segment would represent the largest market share during 2021-2028. Biologics are expected to see strong growth due to the various products in the segment, such as monoclonal antibodies, recombinant proteins, vaccines and others.

Biologics are in increasing demand with increased research and development activities to develop new pharmaceuticals for chronic indications. The COVID-19 pandemic is also expected to drive growth in the biologics segment with increased demand for vaccines against the virus. In addition, monoclonal antibodies are necessary for various chronic diseases of metabolic, infectious, neurological and other origin.

By service, the biopharmaceutical contract management market is segmented into process development, fill and finish operations, analytical and quality control studies, and packaging. The process development segment is expected to hold the largest share of the market during the forecast period due to the largest investments in process development for the production of any biopharmaceutical product.

The focus on commercial-scale pilot process development, cell line development and other processes is expected to create growth opportunities for the process development segment. The segment is further divided into downstream and upstream processing, with downstream processing having the largest share, as downstream processing involves the development of a larger number of products. The analytical and quality control segment is expected to have the highest growth rate.

By source, the biopharmaceutical contract management market is segmented into mammalian- and microbe-based biologics/non-mammalian products.

The mammalian segment is expected to have a larger market share as mammalian cell sources are more commonly used in industry and can develop a wider range of products compared to microbe-based biologics. /non-mammalian sources.

Key Topics Covered:

1. Introduction

2. Biopharmaceutical Contract Manufacturing Market: Key Points

3. Research methodology

4. Biopharmaceutical Contract Manufacturing – Market Landscape

4.1 Summary

4.2 PEST Analysis

4.3 Expert opinion

5. Biopharmaceutical Contract Manufacturing Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Increasing outsourcing by pharmaceutical companies

5.1.2 Growing demand for biological products

5.2 Market restrictions

5.2.1 Increasing competition in the industry

5.3 Market opportunities

5.3.1 Emerging markets

5.4 Future trends

5.4.1 Consolidation in the Pharmaceutical CMO industry

5.4.2 COVID-19 pandemic

5.5 Impact analysis

6. Biopharmaceutical Contract Manufacturing Market – Global Analysis

6.1 Forecast and Revenue Analysis of Global Biopharmaceutical Contract Manufacturing Market

6.2 Global Biopharmaceutical Contract Manufacturing Market, By Geography: Forecast and Analysis

6.3 Market Positioning of Key Players

7. Biopharmaceutical Contract Manufacturing Market Analysis – By Product

7.1 Summary

7.2 Biopharmaceuticals Contract Manufacturing Market Revenue Share, by Product (2021 and 2028)

7.3 Biological

7.3.1 Summary

7.3.2 Biologics – Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (Million US Dollars) Monoclonal antibodies Recombinant proteins Vaccines Others

7.4 Biosimilar

8. Biopharmaceutical contract manufacturing market: by service

8.1 Summary

8.2 Biopharmaceuticals Contract Manufacturing Market, By Service, 2021 and 2028 (%)

8.3 Process development

8.3.1 Summary

8.3.2 Process Development – ​​Biopharmaceuticals Contract Manufacturing Market – Revenue and Forecast to 2028 (Million US Dollars) Further processing Upstream processing

8.4 Filling and finishing operations

8.5 Analytical and Quality Control Studies

8.6 Packaging

9. Biopharmaceutical Contract Manufacturing Market – By Source

9.1 Summary

9.2 Biopharmaceuticals Contract Manufacturing Market, By Source, 2021 and 2028 (%)

9.3 Mammalian-based biologics

9.3.1 Summary

9.3.2 Mammalian-Based Biologics-Biopharmaceuticals Contract Manufacturing Market: Revenue and Forecast to 2028 (Million US Dollars)

9.4 Microbial/Non-Mammalian Based Biologicals

10. Biopharmaceutical Contract Manufacturing Market: Geographic Analysis

11. Impact of the COVID-19 pandemic on the biopharmaceutical contract manufacturing market

12. Biopharmaceutical Contract Manufacturing Market – Industry Landscape

12.1 Summary

12.2 Growth Strategies Performed by Companies in the Market, (%)

12.3 Organic developments

12.4 Inorganic developments

13. Company profiles

  • Lonza AG

  • Boehringer Ingelheim Biopharmaceuticals GmbH

  • Inno Bio Ventures Sdn Bhd

  • ThermoFisher Scientific, Inc.

  • AbbVie, Inc.

  • WuXi Biologics, Inc.

  • general electrical company

  • Samsung Biologics Co. Ltd.

  • Merck KGaA

  • Ajinomoto Co. Inc.

For more information on this report, visit

View the source version on

Laura Wood, Senior Press Officer
For business hours EST call 1-917-300-0470
For US/Canada call toll free 1-800-526-8630
For GMT business hours call +353-1-416-8900

Previous post 12 Personal Finance Influencers to Follow in 2022
Next post Virtual Asset Rumors: Crypto Industry Sees Exits Ahead of New Tax Regime
%d bloggers like this: